Remote blood-draw dried-spot device market seen reaching $1.73B by 2030

The remote blood-draw dried-spot device market is projected to grow from $1.05 billion in 2026 to $1.73 billion by 2030, driven by home healthcare, chronic disease monitoring and personalized medicine. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through 2030.

Why it matters: - Remote blood-draw dried-spot devices let patients collect blood samples at home or other non-clinical settings. - The format supports easier shipping to labs, less invasive testing and more frequent monitoring. - The market’s growth reflects broader demand for patient-centered care, telemedicine and decentralized diagnostics.

What happened: - The Business Research Company released its Remote Blood-Draw Dried-Spot Device Market Report 2026, covering market size, trends and a global forecast for 2026-2035. - The market was estimated at $0.92 billion in 2025 and is forecast to rise to $1.05 billion in 2026. - The market is projected to reach $1.73 billion by 2030, at a 13.2% CAGR. - The report says North America held the largest share of the global market in 2025. - The report says Asia-Pacific is expected to post the fastest growth over the forecast period. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The Business Research Company also offered a free sample of the report. - The company also published the full market report.

The details: - The market’s recent growth has been driven by remote diagnostics, rising demand for patient convenience, expanded laboratory testing services, newborn screening programs and telemedicine. - The forecast growth is tied to home healthcare services, chronic disease monitoring, digital pathology, better sample-transport logistics and population health management. - Expected trends include at-home blood sample collection, mail-in diagnostic testing, minimally invasive sampling, microfluidic blood collection and decentralized diagnostic testing models. - A remote blood-draw dried-spot device collects small blood volumes outside traditional clinical settings, usually at home. - The sample dries on specialized filter paper or absorbent materials and can be shipped to a laboratory for analysis. - The method offers an alternative to conventional venous blood draws for ongoing health monitoring and diagnostic testing. - Personalized medicine is a major growth driver because it depends on frequent blood sampling to track biomarkers and genetic data. - In February 2024, the Personalized Medicine Coalition said the FDA approved 16 new personalized therapies for rare diseases in 2023, up from six in 2022. - Seven of those approvals were cancer-related drugs, and the rest targeted other conditions.

Between the lines: - The market forecast suggests home-based testing is moving from convenience feature to core infrastructure for diagnostics. - Dried-spot collection fits systems that need lower-friction sampling, faster follow-up and broader reach outside hospitals. - The personalized medicine pipeline gives the category a second demand engine beyond routine testing. - The regional split points to a mature North American market and a larger growth runway in Asia-Pacific.

What's next: - The market is expected to keep expanding as more care shifts to homes and outpatient settings. - Adoption should rise as mail-in testing, remote monitoring and decentralized lab models mature. - Future product development will likely focus on simpler collection, better transport stability and easier integration with digital diagnostics. - The report says updated 2026 editions include market attractiveness scoring, TAM analysis, company scoring matrices, forecasting dashboards, hotspot infographics and future-trend analysis.

The bottom line: - Remote blood-draw dried-spot devices are moving into a larger role in diagnostics as health systems seek cheaper, easier and more patient-friendly sample collection.